Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-c...

por Wolf, J., Helland, Å., Oh, I.-J., Migliorino, M.R., Dziadziuszko, R., Wrona, A., de Castro, J., Mazieres, J., Griesinger, F., Chlistalla, M., Cardona, A., Ruf, T., Trunzer, K., Smoljanovic, V., Novello, S.
Publicado 2022

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

por Novello, S, Mazières, J, Oh, I -J, de Castro, J, Migliorino, M R, Helland, Å, Dziadziuszko, R, Griesinger, F, Kotb, A, Zeaiter, A, Cardona, A, Balas, B, Johannsdottir, H K, Das-Gupta, A, Wolf, J
Publicado 2018

Cisplatin-vindesine-mitomycin (MVP) vs cisplatin-ifosfamide-vinorelbine (PIN) vs carboplatin-vinorelbine (CaN) in patients with advanced non-small-cell lung cancer (NSCLC): a FONIC...

por Baldini, E., Tibaldi, C., Ardizzoni, A., Salvati, F., Antilli, A., Portalone, L., Barbera, S., Romano, F., De Marinis, F., Migliorino, M. R., Noseda, M. A., Borghini, U., Crippa, M., Ferrara, G., Raimondi, M., Fioretti, M., Bandera, M., Pennucci, M. C., Galeasso, G., Cacciani, G. C., Lepidini, G., Sunseri, G., Lanfranco, C., Rinaldi, M., Rosso, R.
Publicado 1998